iRGD peptide
Based on 7 publication(s) in Google Scholar
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.49%
- CAS No.: 1392278-76-0
- Formule: C35H57N13O14S2
- Masse moléculaire:948.04
-
Stockage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) iRGD peptide
More- Adv Sci (Weinh). 2025 Nov 21:e10500. [Abstract]
- NPJ Parkinsons Dis. 2023 Jan 31;9(1):13. [Abstract]
- Clin Transl Med. 2021 Oct;11(10):e548. [Abstract]
- J Chem Inf Model. 2023 Oct 23;63(20):6302-6315. [Abstract]
- J Org Chem. 2026 Jun 12;91(23):7758-7768. [Abstract]
- Adv Ther (Weinh). 2021 Apr 14.
- University of Michigan. 2024.
Activité biologique
Integrin[1]
iRGD peptide-mediated tumor penetration occurs in three steps: binding to αv-integrins on tumor vasculature or tumor cells, exposure by proteolysis of a C-terminal motif that binds to neuropilin-1 (NRP-1) and cell internalization. iRGD peptide inserted in the ICOVIR15K fiber C terminus enhances binding and internalization only in MCF7 cells, which express NRP-1 and integrins. iRGD insertion does not impair virus infection and replication[1]. iRGD peptide alone has no obvious effect on gastric cancer cells, and when combined with 5-FU, iRGD peptide (0.3 μmol/mL) enhances the chemotherapy efficacy of 5-FU on gastric cancer cells through NRP1[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1392278-76-0
-
Appearance Solid
-
Masse moléculaire 948.04
-
Formule C35H57N13O14S2
-
Color White to off-white
-
Synonyms
c(CRGDKGPDC)
-
Sequence
Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys (Disulfide bridge:Cys1-Cys9)
-
Sequence Shortening
CRGDKGPDC (Disulfide bridge:Cys1-Cys9)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer. [Abstract]2025 Nov 21:e10500. PMID: 41270217 -
NPJ Parkinsons Dis
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson's disease. [Abstract]2023 Jan 31;9(1):13. PMID: 36720890 -
Clin Transl Med
Targeting integrin αvβ3 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma. [Abstract]2021 Oct;11(10):e548. PMID: 34709754 -
J Chem Inf Model
Molecular View on the i RGD Peptide Binding Mechanism: Implications for Integrin Activity and Selectivity Profiles. [Abstract]2023 Oct 23;63(20):6302-6315. PMID: 37788340 -
J Org Chem
Synthesis of Peptide-Oligonucleotide Conjugates via Condensation of a Lysine Side-Chain with a Thioester. [Abstract]2026 Jun 12;91(23):7758-7768. PMID: 42219707 -
-
Solvant et solubilité
H2O : ≥ 50 mg/mL (52.74 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (105.48 mM); Clear solution; Need ultrasonic
Protocole
Mice[2]
12 male BALB/c nude mice (4-week-old) are assigned to 4 groups with 3 mice in each group. Among them,two groups are subcutaneously injected into the flanks by 3 × 106 HCG27 cells, the other two groups are conducted by NCI-N87 cells. Experimental groups are intravenously injected by 5-FU (25 mg/kg) mixed with iRGD peptide (4 mmol/kg) at every three days for 4 weeks while control groups are treated by 5-FU (25 mg/kg) mixed with PBS. And tumor volume is computed every 1 week with a digital vernier caliper using the following formula: tumor volume = (length × width2)/2[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (286 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Puig-Saus C, et al. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther. 2014 Aug;21(8):767-74. [Content Brief]
[2]. Zhang L, et al. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. Biomed Pharmacother. 2017 Sep;93:1136-1143. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.0548 mL | 5.2740 mL | 10.5481 mL | 26.3702 mL |
| 5 mM | 0.2110 mL | 1.0548 mL | 2.1096 mL | 5.2740 mL | |
| 10 mM | 0.1055 mL | 0.5274 mL | 1.0548 mL | 2.6370 mL | |
| 15 mM | 0.0703 mL | 0.3516 mL | 0.7032 mL | 1.7580 mL | |
| 20 mM | 0.0527 mL | 0.2637 mL | 0.5274 mL | 1.3185 mL | |
| 25 mM | 0.0422 mL | 0.2110 mL | 0.4219 mL | 1.0548 mL | |
| 30 mM | 0.0352 mL | 0.1758 mL | 0.3516 mL | 0.8790 mL | |
| 40 mM | 0.0264 mL | 0.1319 mL | 0.2637 mL | 0.6593 mL | |
| 50 mM | 0.0211 mL | 0.1055 mL | 0.2110 mL | 0.5274 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
iRGD peptide Related Classifications
HY-P0122 Related Classifications
Powered by Bioz